FILAMENT HEALTH ANNOUNCES HEALTH CANADA AUTHORIZATION FOR PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR OPIOID USE DISORDER -October 10, 2023 at 07:31 am EDT
Filament-sponsored analysis will examine its botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, Oct. 10, 2023 /CNW/ – Filament Well being Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (“Filament” or the “Firm“), a medical‐stage…